8-K: Senti Bio Announces Third Quarter 2024 Results and Pipeline Progress

Senti Biosciences reported its Q3 2024 financial results, highlighted by ongoing clinical trials for SENTI-202 and progress in its collaboration for SENTI-301A.

Summary

• Senti Biosciences announced its financial results for the third quarter of 2024, ending September 30, 2024.
• The company is continuing enrollment in the Phase 1 clinical trial of SENTI-202 for relapsed/refractory hematologic malignancies, including AML, with initial clinical data expected by the end of 2024.
• Senti Bio has received $4.9 million of an $8.0 million grant from the California Institute for Regenerative Medicine (CIRM) for the clinical development of SENTI-202.
• They are also developing SENTI-301A for solid tumors in China through a collaboration with Celest Therapeutics, with the first patient dosing expected in Q4 2024.
• As of September 30, 2024, Senti Bio held $10.5 million in cash and cash equivalents.
• Subsequent to the quarter end, they received an additional $2.5 million from CIRM.
• Research and development expenses were $8.7 million for the quarter, a decrease from $9.1 million in the same period of 2023.
• General and administrative expenses were $6.2 million, down from $9.4 million in the same quarter of the previous year.
• The net loss for the quarter was $28.9 million, or $(6.31) per basic and diluted share.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant net loss and decrease in cash reserves, although there is positive progress in clinical trials and collaborations.

Positives

• The Phase 1 clinical trial of SENTI-202 is progressing with patient dosing ongoing.
• Initial safety and efficacy data for SENTI-202 is expected by the end of 2024.
• The company has secured $4.9 million of an $8.0 million grant from CIRM, with an additional $2.5 million received after the quarter end.
• The collaboration with Celest Therapeutics for SENTI-301A is advancing, with first patient dosing expected in Q4 2024.
• Both R&D and G&A expenses have decreased year-over-year, indicating cost management.

Negatives

• The company reported a net loss of $28.9 million for the quarter, or $(6.31) per basic and diluted share.
• Cash and cash equivalents have decreased significantly from $35.9 million at the end of 2023 to $10.5 million as of September 30, 2024.

Risks

• The company's future success is dependent on the outcome of clinical trials, which are subject to risks and uncertainties.
• There are risks associated with the timing and utilization of the grant from CIRM.
• The company is dependent on third parties for clinical trial startup, studies, and GMP manufacturing activities.
• Macroeconomic and geopolitical events, increasing inflation, and rising interest rates could impact business operations.
• The company operates in a highly competitive and regulated industry.

Future Outlook

Senti Bio anticipates sharing initial results from the clinical trial of SENTI-202 before the end of 2024 and additional data, including initial durability data, in 2025. They also expect the first patient dosing for SENTI-301A in China in Q4 2024.

Management Comments

• Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio, stated that they have continued to execute on their clinical milestones and look forward to sharing initial results from the clinical trial of SENTI-202 before 2024 year-end.
• He also mentioned that they anticipate sharing additional data from this trial including initial durability data in 2025.

Industry Context

This announcement is in line with the broader trend of biotechnology companies focusing on clinical trial progress and financial updates. The collaboration with Celest Therapeutics highlights the increasing interest in expanding into the Chinese market for cell and gene therapies.

Comparison to Industry Standards

• Senti Bio's cash burn rate is high, with a net loss of $28.9 million for the quarter, which is not uncommon for clinical-stage biotech companies.
• The company's R&D expenses of $8.7 million are typical for a company in its stage of development, focusing on clinical trials.
• The collaboration with Celest Therapeutics is similar to other biotech companies partnering to expand into new markets, such as Legend Biotech's collaboration with Janssen for CAR-T therapy in China.
• The $8 million grant from CIRM is a significant non-dilutive funding source, similar to grants received by other biotech companies like Sangamo Therapeutics from the California Institute for Regenerative Medicine.

Related Party Transactions

• Research and development expenses included related party costs of $3.79 million and $1.19 million for the three months ended September 30, 2024 and 2023, respectively, and $11.06 million and $1.19 million for the nine months ended September 30, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders may be concerned about the significant net loss and decrease in cash reserves.
• Employees may be affected by the reduction in headcount, which contributed to lower operating expenses.
• The progress in clinical trials and collaborations is positive for patients who may benefit from the therapies.
• The company's financial position may impact its ability to secure future funding and partnerships.

Next Steps

• Senti Bio plans to share initial results from the clinical trial of SENTI-202 before the end of 2024.
• The company anticipates sharing additional data from the SENTI-202 trial, including initial durability data, in 2025.
• Celest Therapeutics expects to dose the first patient in the pilot trial for SENTI-301A in China in the fourth quarter of 2024.
• Senti Bio plans to participate in the Immunotherapy Bridge 2024 and the American Society of Hematology 2024 conferences.

Key Dates

Keywords

Senti Bio, SENTI-202, SENTI-301A, Clinical Trial, Gene Therapy, AML, Hematologic Malignancies, CIRM, Celest Therapeutics, Financial Results